12:29 AM EDT, 07/13/2026 (MT Newswires) -- AB Science (AB.PA) said July 10 that it will discontinue three clinical developments related to its drug under development masitinib. The Paris-listed pharmaceutical company said it will close, in line with regulations, the phase 2 trial in mast cell activation syndrome, the phase 2 trial in mastocytosis and the phase 3 trial in progressive forms of multiple sclerosis. The company noted that discontinuing the studies will allow it to focus on its AB8939 program for acute myeloid leukemia and the masitinib program for amyotrophic lateral sclerosis.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.